Collecting blood and tissue samples from patients with gastrointestinal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather blood and tumor tissue samples from individuals diagnosed with gastrointestinal cancers, such as throat, stomach, gallbladder, liver, pancreatic, or colon cancer. The objective is to analyze the immune system's response to these cancers and understand the role of gut microbiota in cancer progression. Participants will undergo a screening process and provide baseline samples during one to four visits to the National Institutes of Health Clinical Center. The findings may help inform future immunotherapy approaches and improve treatment strategies.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:
* Individuals 18 years of age and older
* Individuals with a diagnosis of cancer
* Individuals must be able to understand and willing to sign a written informed consent document

EXCLUSION CRITERIA:

-None

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Tim F Greten, M.D. — National Cancer Institute (NCI)
• Study coordinator: Stephanie N Hicks
• Email: hickssn2@nih.gov
• Phone: (240) 760-6159

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Frailty before GI cancer surgery: does frailty predict post-op outcomes in older adults?

  This study tests whether frailty measured before surgery can predict complications and recovery in patients 60 and older undergoing elective gastrointestinal cancer surgery.

  Recruiting Van Training and Research Hospital · Van, Van · NCT07815392

• Biological Collection to Help Create Models for Digestive Cancers and IBD

  Researchers are gathering tissue and biological samples from patients with inflammatory bowel disease or digestive cancers to build personalized models and test new therapies.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07782203

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

• XH001 with neoantigen vaccine–primed tumor-specific T cells for advanced gastrointestinal cancer

  This trial tests whether combining XH001 injections with T cells activated by a tumor neoantigen vaccine is safe and can shrink tumors or extend life in adults with advanced gastrointestinal cancer.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07329894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.